In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better... Continue Reading

The US Food and Drug Administration (FDA) has approved the targeted therapy Erivedge™ (vismodegib) for the treatment basal cell carcinoma of the skin that has spread to other parts of the body or that... Continue Reading

The US Food and Drug Administration has approved Inlyta® (axitinib) for the treatment of advanced renal cell (kidney) cancer that has not responded to another drug used for this condition. Inlyta is a... Continue Reading

Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program THOUSAND OAKS, Calif., (Dec. 6, 2011) – Amgen (NASDAQ:AMGN) today announced the U.S. Food and... Continue Reading

The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy... Continue Reading

The U.S. Food and Drug Administration (FDA) has expanded the approval of Prolia® (denosumab) to include treatment of bone loss among breast cancer patients treated with aromatase inhibitor therapy and... Continue Reading

The targeted drug Xalkori™ (crizotinib) has been approved by the US Food and Drug Administration for the treatment of advanced non-small lung cancer that has an abnormal version of the ALK gene. Lung... Continue Reading

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic... Continue Reading

The targeted therapy Zelboraf™ (vemurafenib) has been approved by the US Food and Drug Administration (FDA) for the treatment of melanomas that carry a common mutation in the BRAF gene. Of the more than... Continue Reading

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type... Continue Reading